Elective hysterectomy. Benefits, risks, and costs

other public-domain-us
View on PubMed
AI-generated summary by gemini-2.5-flash-lite, 2026-07-15

Elective hysterectomy for benign gynecologic conditions improves life expectancy and quality of life for women ages 30-60 by preventing cancer, but risks include operative mortality and potential life expectancy loss for those with high operative risk or younger women not on estrogen replacement.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

This study evaluated the effect of hysterectomy or hysterectomy and bilateral salpingo-oophorectomy (hysterectomy and oophorectomy) versus alternative medical management on life expectancy, quality of life, and direct medical costs. Using techniques of decision analysis and available data on sequelae, it was found that gains in life expectancy and quality of life can be expected when women ages 30-60 undergo hysterectomy for benign neoplasm, disorders of menstruation, acquired abnormal anatomy, cervical disease, or endometriosis, owing primarily to prevention of reproductive tract cancers, which outweighs the impact of operative mortality. However, women who have relatively high operative risk or low expected cancer risks, beyond thresholds estimated in sensitivity analyses, suffer losses in life expectancy. Women younger than 35 not treated with replacement estrogens following hysterectomy and oophorectomy can expect net losses in life expectancy with surgical intervention due to increased risks of heart disease and osteoporosis. For women in the reproductive years who wish to preserve their potential to bear children, sterilization may be an unacceptable consequence of elective hysterectomy in the quality of life.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Hysterectomy Hysterectomy Hysterectomy Hysterectomy Adult Age Factors Castration Contraception Contraception Coronary Disease Coronary Disease Coronary Disease Cost-Benefit Analysis Decision Theory Estrogens Estrogens Fallopian Tubes Fallopian Tubes Female Genital Diseases, Female

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-09-15T06:16:59.523076+00:00
pubmed
last seen: 2026-05-13T22:09:45.632124+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine